Orion Corporation
https://www.orion.fi/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orion Corporation
Merck Takes Over Orion-Partnered Prostate Cancer Drug MK-5684
Deal Snapshot: Merck said it would pay potentially more than $1.6bn for an exclusive global license for opevesostat for metastatic castrate-resistant prostate cancer.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Vaccines
-
Drug Delivery
- Pulmonary
- Other Names / Subsidiaries
-
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice